about
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approachInsulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer RiskBevacizumab in ovarian cancer: A critical review of phase III studiesThe clinical implementation of primary HPV screening.Fertility drugs, reproductive strategies and ovarian cancer risk.Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients.The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.Triple-negative breast cancer: new perspectives for targeted therapies.DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 studyBody mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients.Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapyRecurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysisIs the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohortAnalysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment."Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic reviewFOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studiesEmerging biological treatments for uterine cervical carcinoma.Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.Immunologic treatments for precancerous lesions and uterine cervical cancer.Hot flushes in women with breast cancer: state of the art and future perspectives.Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations.Cancer stem cells: are they responsible for treatment failure?Metformin and breast cancer: basic knowledge in clinical context.Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications.Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions.
P50
Q26849477-D1BA77E3-4A4C-480D-B1AD-7D266BE79860Q28072521-6FF685C2-5AD6-4AB4-8A54-2673441165AEQ28076188-0831855C-AE3E-4C30-B8BA-0DEE0BAA4432Q30238954-B9387498-E443-41CA-81E5-DB249992D31AQ33608317-43EAB3CF-F8F6-445F-9399-7B83D946F8AEQ33634964-EC4CBDC2-625C-451B-B299-6DC2391940F6Q34654520-F3A3FF44-E9F7-4B58-845B-73542F133645Q34658209-9E91F1EA-637C-4817-AC3E-08A7BBD0CBDDQ34786457-1641305B-AD4C-4CE7-9C37-337EFC89CAF2Q35001758-DE243F19-5429-4037-881D-FF33A9185DF9Q35941085-0B4E22C9-DC1E-4A00-BFF1-8F6849322197Q35994850-8ED623A6-89D6-4AF4-8B01-66C3A3484F8EQ36272043-142EE506-3649-496B-8BD8-B174E88F4CEBQ36619000-94A74D6A-9A14-453E-B4D1-35E06BE059E9Q36657326-3265CB21-691C-4873-9401-6CC7698F4B60Q36759772-3FA5796A-E7B3-40F5-A624-5479DC61BD75Q36762888-6D80A08A-3F2B-461C-A0E1-A1508A71BACAQ36843741-96970BDB-7CB0-4A89-9828-FB5F50C09A09Q37013245-0228CAA4-0187-4CE5-A042-044F258DDD0DQ37079126-866B67B6-4A8B-4BB4-BD7A-ADE5418BA6FAQ37109643-11CFA251-5EF3-4A89-ABBF-55566E0E9404Q37113732-3C64321D-83AF-4489-BDCA-5D37AA45967AQ37309845-E04BE69F-57E8-4E7C-A900-D13F6C2FBB94Q37362737-62F5B473-AFC9-43BA-B9CE-EFB304BFB8A2Q37491455-6A22D99A-ABF4-4A93-96EB-E03BF5AC396AQ37494787-54E23897-7406-4B9F-91D9-D1F44F784EA9Q37540968-5BD433DE-692C-47A8-B958-B1F4D2CDA63FQ37695495-0B3E3213-E56B-4681-88DE-0D6D1AFC7FB4Q37703113-DFC318A0-6230-4DA9-925E-949128D8134BQ38169220-26DCF2FB-15FD-409B-AAA4-04500DFD24A3Q38239410-B1EA5240-7EFE-4DA5-A948-13BC89957978Q38268164-7B1E7045-88F6-4D78-9ECB-B4203C85159AQ38393632-055E837B-A539-40D5-8706-15C0E1AFA4ACQ38537836-16B78144-1E84-41B8-97AB-03EEE0902AA7Q38542016-AA2504E9-F1DE-426D-AA11-B712AF60C32AQ38631272-C0AB8DC0-FF1C-4BA9-8AF1-620CF1BB224EQ38677321-E275100A-05D0-47BB-8A89-F96256200BFDQ38677841-65808406-7884-4370-B8FD-82C4592E210FQ38764762-2602A57D-35BF-46D5-9D60-56485F3F5D61Q38787343-B4B9668B-4977-428A-9E35-175BCB676836
P50
description
researcher (ORCID 0000-0001-7528-9783)
@en
name
Patrizia Vici
@en
type
label
Patrizia Vici
@en
prefLabel
Patrizia Vici
@en
P31
P496
0000-0001-7528-9783